Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RGS4 | P49798 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | CRHBP | P24387 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16158991 | 0.89 | RGS4 (0.52) | RGS4KMT2AALDH1A1TP53MAPT | |
| SCHEMBL3470063 | 0.89 | RGS4 (0.55) | RGS4KMT2AALDH1A1TP53MAPT | |
| SCHEMBL3201607 | 0.79 | RGS4 (0.64) | RGS4KMT2AALDH1A1MAPT | |
| SCHEMBL10926180 | 0.76 | CASP3 (0.56) | KMT2ATP53MAPT | |
| SCHEMBL3201920 | 0.73 | APLNR (0.48) | RGS4KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL13698258 | 0.72 | KMT2A (0.55) | KMT2AALDH1A1TP53MAPTSMN1; SMN2 | |
| SCHEMBL4852710 | 0.70 | RGS4 (0.70) | RGS4ALDH1A1MAPTLMNA | |
| SCHEMBL4848605 | 0.70 | RGS4 (1.00) | RGS4KMT2AALDH1A1 | |
| SCHEMBL4628903 | 0.69 | KMT2A (0.55) | KMT2AALDH1A1TP53MAPTSMN1; SMN2 | |
| SCHEMBL15276187 | 0.69 | KMT2A (0.70) | KMT2AALDH1A1TP53MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170204088-A1 | NOVEL 1-HETEROARYL-3-AZABICYCLO[3.1.0]HEXANES, METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | ETHISMOS RESEARCH, INC. | 2017-07-20 | — | — | US | disclosed |
| US-9597315-B2 | 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments | EUTHYMICS BIOSCIENCE, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160022634-A1 | NOVEL 1-HETEROARYL-3-AZABICYCLO[3.1.0]HEXANES, METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | ETHISMOS RESEARCH, INC. | 2016-01-28 | — | — | US | disclosed |
| US-9133159-B2 | 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments | NEUROVANCE, INC. (US) | 2015-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022634-A1 | NOVEL 1-HETEROARYL-3-AZABICYCLO[3.1.0]HEXANES, METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | HTR3C, HTR2C, GRIN2C | RGS4 1048/4885KMT2A 1841/4885ALDH1A1 372/4885 |
| US-20170204088-A1 | NOVEL 1-HETEROARYL-3-AZABICYCLO[3.1.0]HEXANES, METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | HTR3C, HTR2C, GRIN2C | RGS4 1048/4885KMT2A 1841/4885ALDH1A1 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.